Difficult-to-Control Type 2 Diabetes (T2D) and Hypertension May Be Masking a Bigger Threat

According to recent research, hypercortisolism may be more prevalent than previously believed.1

It may not be seen, unless you screen.

EXPLORE SCREENING GUIDELINES

Could Hypercortisolism be driving your patients’ high blood sugar and/or blood pressure?Learn More About Recently Published Prevalence Data

In patients with difficult-to-control T2D*

Nearly 1 in 4 (24%) were identified to have endogenous hypercortisolism1

View difficult-to-control T2D data

In patients with difficult-to-control T2D* and hypertension

More than 1 in 3 (37%) were identified to have endogenous hypercortisolism1

View hypertension data

Left untreated, hypercortisolism can lead to a greater risk for cardiovascular morbidity and mortality2

Hypercortisolism screening is the first step

DST, dexamethasone suppression test; T2D, type 2 diabetes.

*Difficult-to-control T2D with diagnosis ≥1 year prior was defined as patients having an HbA1c of 7.5% - 11.5% and taking: ≥3 T2D medications OR insulin and other T2D medication(s) OR ≥2 T2D medications AND the presence of ≥1 microvascular or macrovascular complications AND/OR concomitant hypertension requiring ≥2 hypertension medications.4

Patients in the CATALYST study with difficult-to-control T2D who were taking ≥3 hypertension medications.1

References

1. Buse JB, Kahn SE, Aroda VR, et al. Diabetes Care. 2025;48(00):1-9. doi:10.2337/dc24-2841 2. Petramala L, Olmati F, Concistrè A, et al. Endocrine. 2020;70(1):150-163. doi:10.1007/s12020-020-02297-2 3. Ciftel S, Mercantepe F. Cureus. 2023;15(11):e48383. doi:10.7759/cureus.48383 4. DeFronzo RA, Auchus RJ, Bancos I, et al. BMJ Open. 2024;14(7):e081121. doi:10.1136/bmjopen-2023-081121 5. Nieman LK, Biller BM, Findling JW, et al. J Clin Endocrinol Metab. 2008;93(5):1526-1540. doi:10.1210/jc.2008-0125